Overview

A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-10

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active control in localized cutaneous leishmaniasis in the region of the Americas (AMR), and assess its suitability for use in monotherapy for the treatment of patients with cutaneous leishmaniasis (CL).

Phase:

PHASE2

Details

Lead Sponsor:

Drugs for Neglected Diseases

Collaborator:

Novartis Pharmaceuticals

Treatments:

LXE408
miltefosine